REGiMMUNE
Taipei, Taiwan· Est.
Treg‑focused biotech delivering novel immunotherapies for GvHD, autoimmunity and oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Treg‑focused biotech delivering novel immunotherapies for GvHD, autoimmunity and oncology.
OncologyImmunology
Technology Platform
Liposomal alpha‑galactosylceramide analogs that expand Tregs and antibodies that selectively deplete activated Tregs via ADCC.
Opportunities
Expansion of Treg‑enhancing therapy into broader transplant and autoimmune markets, and combination of Treg‑suppressing antibodies with checkpoint inhibitors in oncology.
Risk Factors
Clinical efficacy uncertainty, regulatory hurdles for novel liposomal small molecules, and competition from larger immuno‑oncology firms developing Treg‑targeted agents.
Competitive Landscape
Key competitors include companies such as Novartis, Kite Pharma, and Allogene Therapeutics that also explore Treg modulation, but REGiMMUNE differentiates through its liposomal small‑molecule platform and highly selective Treg‑depleting antibodies.